Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.14.11.67 - [histone H3]-trimethyl-L-lysine4 demethylase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Lysine-specific demethylase 2A expression is associated with cell growth and cyclin D1 expression in colorectal adenocarcinoma.
Adenocarcinoma of Lung
Histone demethylase KDM5A enhances cell proliferation, induces EMT in lung adenocarcinoma cells, and have a strong causal association with paclitaxel resistance.
African Swine Fever
An ARID family protein binds to the African swine fever virus encoded ubiquitin conjugating enzyme, UBCv1.
Aortic Valve Stenosis
Induction by left ventricular overload and left ventricular failure of the human Jumonji gene (JARID2) encoding a protein that regulates transcription and reexpression of a protective fetal program.
Ataxia
A novel de novo KDM5C variant in a female with global developmental delay and ataxia: a case report.
Breast Neoplasms
A KDM5 Inhibitor Increases Global H3K4 Trimethylation Occupancy and Enhances the Biological Efficacy of 5-Aza-2'-Deoxycytidine.
A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer.
A short region of the promoter of the breast cancer associated PLU-1 gene can regulate transcription in vitro and in vivo.
Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14.
Characterisation and developmental expression of mouse Plu-1, a homologue of a human nuclear protein (PLU-1) which is specifically up-regulated in breast cancer.
Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
Crystallization and preliminary crystallographic analysis of a PHD domain of human JARID1B.
Expression of ANRIL-Polycomb Complexes-CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value.
Extended Recognition of the Histone H3 Tail by Histone Demethylase KDM5A.
FBXL10 promotes ERR? protein stability and proliferation of breast cancer cells by enhancing the mono-ubiquitylation of ERR?.
Genome-Wide Methylation Analysis Identifies NOX4 and KDM5A as Key Regulators in Inhibiting Breast Cancer Cell Proliferation by Ginsenoside Rg3.
Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer.
Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression.
Histone demethylase jumonji AT-rich interactive domain 1B (JARID1B) controls mammary gland development by regulating key developmental and lineage specification genes.
Identification of Small Molecule Inhibitors of Jumonji AT-rich Interactive Domain 1B (JARID1B) Histone Demethylase by a Sensitive High Throughput Screen.
Immunohistochemical detection and clinicopathological significance of JARID1B/KDM5B and P16 expression in invasive ductal carcinoma of the breast.
Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells.
Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells.
JARID1B expression and its function in DNA damage repair are tightly regulated by miRNAs in breast cancer.
JARID1B is a luminal lineage-driving oncogene in breast cancer.
JARID1B modulates breast cancer cell apoptosis by regulating p53 expression.
KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance.
KDM5B promotes breast cancer cell proliferation and migration via AMPK-mediated lipid metabolism reprogramming.
Long noncoding RNA RHPN1-AS1, induced by KDM5B, is involved in breast cancer via sponging miR-6884-5p.
Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53.
MicroRNAs regulate KDM5 histone demethylases in breast cancer cells.
Phosphorylation of the histone demethylase KDM5B and regulation of the phenotype of triple negative breast cancer.
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation.
PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/testis antigen?
PLU-1/JARID1B/KDM5B is required for embryonic survival and contributes to cell proliferation in the mammary gland and in ER+ breast cancer cells.
Recruitment of the Mammalian Histone-modifying EMSY Complex to Target Genes Is Regulated by ZNF131.
Relevance of c-erbB2, PLU-1 and survivin mRNA expression to diagnostic assessment of breast cancer.
Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B.
Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines.
T cells reactive with HLA-A*0201 peptides from the histone demethylase JARID1B are found in the circulation of breast cancer patients.
The Dual Function of KDM5C in Both Gene Transcriptional Activation and Repression Promotes Breast Cancer Cell Growth and Tumorigenesis.
The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers.
Tumor mutation burden and JARID2 gene alteration are associated with short disease-free survival in locally advanced triple-negative breast cancer.
Unliganded progesterone receptor-mediated targeting of an RNA-containing repressive complex silences a subset of hormone-inducible genes.
Bronchiolitis
Balancing precision versus cohort transcriptomic analysis of acute and recovery phase of viral bronchiolitis.
Carcinogenesis
Evidence of Omics, Immune Infiltration, and Pharmacogenomic for SENP1 in the Pan-Cancer Cohort.
Expression of Lysine-specific demethylase 1 in human epithelial ovarian cancer.
FBXL10 promotes ERR? protein stability and proliferation of breast cancer cells by enhancing the mono-ubiquitylation of ERR?.
Fbxl10/Kdm2b deficiency accelerates neural progenitor cell death and leads to exencephaly.
H3K4me3 Demethylase Kdm5a Is Required for NK Cell Activation by Associating with p50 to Suppress SOCS1.
Histone Demethylase JARID1B is Overexpressed in Osteosarcoma and Upregulates Cyclin D1 Expression Via Demethylation of H3K27me3.
Histone demethylase JARID1B promotes cell proliferation but is downregulated by N-Myc oncoprotein.
Histone demethylase JARID1B/KDM5B is a corepressor of TIEG1/KLF10.
Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor.
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Histone demethylase KDM5A is an integral part of the core Notch-RBP-J repressor complex.
Histone demethylase KDM5A promotes tumorigenesis of osteosarcoma tumor.
Hypoxia Induces Trimethylated H3 Lysine 4 by Inhibition of JARID1A Demethylase.
Jarid2 enhances the progression of bladder cancer through regulating PTEN/AKT signaling.
Jumonji AT-rich interactive domain 1B overexpression is associated with the development and progression of glioma.
KDM5A silencing transcriptionally suppresses the FXYD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation.
KDM5B is essential for the hyper-activation of PI3K/AKT signaling in prostate tumorigenesis.
KDM5B is overexpressed in gastric cancer and is required for gastric cancer cell proliferation and metastasis.
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.
Marek's disease: Genetic regulation of gallid herpesvirus 2 infection and latency.
MicroRNAs regulate KDM5 histone demethylases in breast cancer cells.
miR-194 inhibits gastric cancer cell proliferation and tumorigenesis by targeting KDM5B.
Outcome after surgery for primary hyperaldosteronism may depend on KCNJ5 tumor mutation status: a population-based study from Western Norway.
Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway.
Prognostic value of elevated KDM5B expression in patients with laryngeal squamous cell carcinoma.
SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination.
The Dual Function of KDM5C in Both Gene Transcriptional Activation and Repression Promotes Breast Cancer Cell Growth and Tumorigenesis.
The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers.
The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis.
Carcinoma
Blockade of Immune-Checkpoint B7-H4 and Lysine Demethylase 5B in Esophageal Squamous Cell Carcinoma Confers Protective Immunity against P. gingivalis Infection.
Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
Connexin 26 is Down-Regulated by KDM5B in the Progression of Bladder Cancer.
Deficiency of the X-inactivation escaping gene KDM5C in clear cell renal cell carcinoma promotes tumorigenicity by reprogramming glycogen metabolism and inhibiting ferroptosis.
Epigenetic modifiers: activities in renal cell carcinoma.
Expression pattern and regulatory effect of lysine-specific demethylase 2A gene in clear cell renal cell carcinoma.
Gender Specific Mutation Incidence and Survival Associations in Clear Cell Renal Cell Carcinoma (CCRCC).
Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma.
Genomic Landscape of Chinese Clear Cell Renal Cell Carcinoma Patients With Venous Tumor Thrombus Identifies Chromosome 9 and 14 Deletions and Related Immunosuppressive Microenvironment.
Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.
Jumonji Inhibitors Overcome Radioresistance in Cancer through Changes in H3K4 Methylation at Double-Strand Breaks.
KDM5B overexpression predicts a poor prognosis in patients with squamous cell carcinoma of the head and neck.
Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma.
Loss of PBRM1 expression is associated with renal cell carcinoma progression.
LSD1 regulates Notch and PI3K/Akt/mTOR pathways through binding the promoter regions of Notch target genes in esophageal squamous cell carcinoma.
microRNA-486-5p functions as a tumor suppressor in gastric carcinoma via directly targeting KDM5B.
miR-194 inhibits proliferation and invasion and promotes apoptosis by targeting KDM5B in esophageal squamous cell carcinoma cells.
Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer.
Overexpression of JARID1B promotes differentiation via SHIP1/AKT signaling in human hypopharyngeal squamous cell carcinoma.
Overexpression of Jumonji AT-rich interactive domain 1B and PHD finger protein 2 is involved in the progression of esophageal squamous cell carcinoma.
Prognostic value of elevated KDM5B expression in patients with laryngeal squamous cell carcinoma.
Radiogenomics of Clear Cell Renal Cell Carcinoma: Associations between CT Imaging Features and Mutations.
Relevance of c-erbB2, PLU-1 and survivin mRNA expression to diagnostic assessment of breast cancer.
Silencing JARID1B suppresses oncogenicity, stemness and increases radiation sensitivity in human oral carcinoma.
Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
[Sonic hedgehog signaling enhanced the expression of histone demethylase, lysine-specific demethylase 8 in the head and neck squamous cell carcinoma cell line SCC-6].
Carcinoma, Ductal
Relevance of c-erbB2, PLU-1 and survivin mRNA expression to diagnostic assessment of breast cancer.
Carcinoma, Hepatocellular
Correction: JARID1B promotes metastasis and epithelial-mesenchymal transition via PTEN/AKT signaling in hepatocellular carcinoma cells.
Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27.
Extended Recognition of the Histone H3 Tail by Histone Demethylase KDM5A.
Hepatitis B virus X protein induces hepatic stem cell-like features in hepatocellular carcinoma by activating KDM5B.
Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212.
Increased Expression of Lysine-Specific Demethylase 5B (KDM5B) Promotes Tumor Cell Growth in Hep3B Cells and is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma.
JARID1B promotes metastasis and epithelial-mesenchymal transition via PTEN/AKT signaling in hepatocellular carcinoma cells.
JARID2 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition through PTEN/AKT signaling.
KDM5B promotes self-renewal of hepatocellular carcinoma cells through the microRNA-448-mediated YTHDF3/ITGA6 axis.
Lysine-specific demethylase 5C promotes hepatocellular carcinoma cell invasion through inhibition BMP7 expression.
MiR-22 regulated T cell differentiation and hepatocellular carcinoma growth by directly targeting Jarid2.
Overexpression of KDM5B/JARID1B is associated with poor prognosis in hepatocellular carcinoma.
Carcinoma, Non-Small-Cell Lung
JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression.
JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1.
Long non-coding RNA KDM5B anti-sense RNA 1 enhances tumor progression in non-small cell lung cancer.
Metformin-induced chemosensitization to cisplatin depends on P53 status and is inhibited by Jarid1b overexpression in non-small cell lung cancer cells.
Overcoming of Radioresistance in Non-small Cell Lung Cancer by microRNA-320a Through HIF1?-Suppression Mediated Methylation of PTEN.
Retinoblastoma binding protein 2 (RBP2) promotes HIF-1?-VEGF-induced angiogenesis of non-small cell lung cancer via the Akt pathway.
Carcinoma, Ovarian Epithelial
Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer.
Carcinoma, Renal Cell
Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
Deficiency of the X-inactivation escaping gene KDM5C in clear cell renal cell carcinoma promotes tumorigenicity by reprogramming glycogen metabolism and inhibiting ferroptosis.
Epigenetic modifiers: activities in renal cell carcinoma.
Expression pattern and regulatory effect of lysine-specific demethylase 2A gene in clear cell renal cell carcinoma.
Gender Specific Mutation Incidence and Survival Associations in Clear Cell Renal Cell Carcinoma (CCRCC).
Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma.
Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.
Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma.
Loss of PBRM1 expression is associated with renal cell carcinoma progression.
Radiogenomics of Clear Cell Renal Cell Carcinoma: Associations between CT Imaging Features and Mutations.
Carcinoma, Squamous Cell
Jumonji Inhibitors Overcome Radioresistance in Cancer through Changes in H3K4 Methylation at Double-Strand Breaks.
KDM5B overexpression predicts a poor prognosis in patients with squamous cell carcinoma of the head and neck.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
[Sonic hedgehog signaling enhanced the expression of histone demethylase, lysine-specific demethylase 8 in the head and neck squamous cell carcinoma cell line SCC-6].
Cardiomyopathies
Mutations of histone demethylase genes encoded by X and Y chromosomes, Kdm5c and Kdm5d, lead to noncompaction cardiomyopathy in mice.
Cardiomyopathy, Dilated
Myocardial-specific ablation of Jumonji and AT-rich interaction domain-containing 2 (Jarid2) leads to dilated cardiomyopathy in mice.
CHARGE Syndrome
Knockdown of fbxl10/kdm2bb rescues chd7 morphant phenotype in a zebrafish model of CHARGE syndrome.
Cholangiocarcinoma
KDM5C Represses FASN-Mediated Lipid Metabolism to Exert Tumor Suppressor Activity in Intrahepatic Cholangiocarcinoma.
Cleft Lip
Brazilian multicenter study of association between polymorphisms in CRISPLD2 and JARID2 and non-syndromic oral clefts.
Expression and association data strongly support JARID2 involvement in nonsyndromic cleft lip with or without cleft palate.
Possible effect of SNAIL family transcriptional repressor 1 polymorphisms in non-syndromic cleft lip with or without cleft palate.
Cleft Palate
Brazilian multicenter study of association between polymorphisms in CRISPLD2 and JARID2 and non-syndromic oral clefts.
Expression and association data strongly support JARID2 involvement in nonsyndromic cleft lip with or without cleft palate.
Possible effect of SNAIL family transcriptional repressor 1 polymorphisms in non-syndromic cleft lip with or without cleft palate.
Colitis
MiR-155 contributes to Th17 cells differentiation in dextran sulfate sodium (DSS)-induced colitis mice via Jarid2.
MiR-155 inhibition ameliorates 2, 4, 6-Trinitrobenzenesulfonic acid (TNBS)-induced experimental colitis in rat via influencing the differentiation of Th17 cells by Jarid2.
Coloboma
Fbxl10/Kdm2b deficiency accelerates neural progenitor cell death and leads to exencephaly.
Colonic Neoplasms
JARID2 inhibits leukemia cell proliferation by regulating CCND1 expression.
JARID2 is involved in transforming growth factor-beta-induced epithelial-mesenchymal transition of lung and colon cancer cell lines.
KDM5c inhibits multidrug resistance of colon cancer cell line by down-regulating ABCC1.
KDM5c Promotes Colon Cancer Cell Proliferation Through the FBXW7-c-Jun Regulatory Axis.
Colorectal Neoplasms
Depletion of JARID1B induces cellular senescence in human colorectal cancer.
JARID1B promotes colorectal cancer proliferation and Wnt/?-catenin signaling via decreasing CDX2 level.
Lysine demethylase 5B suppresses CC chemokine ligand 14 to promote progression of colorectal cancer through the Wnt/?-catenin pathway.
Dehydration
Arabidopsis histone H3K4 demethylase JMJ17 functions in dehydration stress response.
Diabetic Cardiomyopathies
FBXL10 regulates cardiac dysfunction in diabetic cardiomyopathy via the PKC ?2 pathway.
Diffuse Intrinsic Pontine Glioma
Targeting of Histone Demethylases KDM5A and KDM6B Inhibits the Proliferation of Temozolomide-Resistant Glioblastoma Cells.
Endometriosis
Peritoneal Modulators of EZH2-miR-155 Cross-Talk in Endometriosis.
Epilepsy
A regulatory path associated with X-linked intellectual disability and epilepsy links KDM5C to the polyalanine expansions in ARX.
Novel microduplications at Xp11.22 including HUWE1: clinical and molecular insights into these genomic rearrangements associated with intellectual disability.
Variable Phenotypes of Epilepsy, Intellectual Disability, and Schizophrenia Caused by 12p13.33-p13.32 Terminal Microdeletion in a Korean Family: A Case Report and Literature Review.
Esophageal Neoplasms
Jumonji/Arid1b (Jarid1b) protein modulates human esophageal cancer cell growth.
MicroRNA let-7i Inhibits Histone Lysine Demethylase KDM5B to Halt Esophageal Cancer Progression.
Esophageal Squamous Cell Carcinoma
Blockade of Immune-Checkpoint B7-H4 and Lysine Demethylase 5B in Esophageal Squamous Cell Carcinoma Confers Protective Immunity against P. gingivalis Infection.
LSD1 regulates Notch and PI3K/Akt/mTOR pathways through binding the promoter regions of Notch target genes in esophageal squamous cell carcinoma.
miR-194 inhibits proliferation and invasion and promotes apoptosis by targeting KDM5B in esophageal squamous cell carcinoma cells.
Overexpression of Jumonji AT-rich interactive domain 1B and PHD finger protein 2 is involved in the progression of esophageal squamous cell carcinoma.
Familial Primary Pulmonary Hypertension
Long Noncoding RNA MANTIS Facilitates Endothelial Angiogenic Function.
Glioblastoma
Inhibition of lysine-specific demethylase LSD1 induces senescence in Glioblastoma cells through a HIF-1?-dependent pathway.
Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
Targeting of Histone Demethylases KDM5A and KDM6B Inhibits the Proliferation of Temozolomide-Resistant Glioblastoma Cells.
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Glioma
Histone demethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1.
Jumonji AT-rich interactive domain 1B overexpression is associated with the development and progression of glioma.
Overexpressed KDM5B is associated with the progression of glioma and promotes glioma cell growth via downregulating p21.
Reduced expression of Jumonji, AT-rich interactive domain 2 (JARID2) in glioma inhibits tumor growth in vitro and in vivo.
SNHG1 promotes malignant biological behaviors of glioma cells via microRNA-154-5p/miR-376b-3p- FOXP2- KDM5B participating positive feedback loop.
Targeting of Histone Demethylases KDM5A and KDM6B Inhibits the Proliferation of Temozolomide-Resistant Glioblastoma Cells.
The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ).
[Corrigendum] Jumonji AT-rich interactive domain 1B overexpression is associated with the development and progression of glioma.
Head and Neck Neoplasms
KDM5 histone demethylases repress immune response via suppression of STING.
Heart Defects, Congenital
Epigenetic mechanisms in cardiac development and disease.
Heart Diseases
Cardiac-specific developmental and epigenetic functions of Jarid2 during embryonic development.
Heart Failure
Comprehensive Myocardial Proteogenomics Profiling Reveals C/EBP? as the Key Factor in the Lipid Storage of ARVC.
DNA methylation patterns from peripheral blood separate coronary artery disease patients with and without heart failure.
Identification of circulating placental mRNA in maternal blood of pregnancies affected with fetal congenital heart diseases at the second trimester of pregnancy: implications for early molecular screening.
Heart Septal Defects, Ventricular
Cardiac-specific developmental and epigenetic functions of Jarid2 during embryonic development.
Hepatitis B
Hepatitis B virus X protein induces hepatic stem cell-like features in hepatocellular carcinoma by activating KDM5B.
Hirschsprung Disease
KDM5B promotes cell migration by regulating the noncanonical Wnt/PCP pathway in Hirschsprung's disease.
Hyperglycemia
Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail.
Hyperglycinemia, Nonketotic
Identification of a RAI1-associated disease network through integration of exome sequencing, transcriptomics, and 3D genomics.
Hypersensitivity
Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.
Hypertension
Long Noncoding RNA MANTIS Facilitates Endothelial Angiogenic Function.
The phenotypic impact of the male-specific region of chromosome-Y in inbred mating: the role of genetic variants and gene duplications in multiple inbred rat strains.
Hypertension, Pulmonary
Histone demethylase JARID1B regulates proliferation and migration of pulmonary arterial smooth muscle cells in mice with chronic hypoxia-induced pulmonary hypertension via nuclear factor-kappa B (NFkB).
Infections
Blockade of Immune-Checkpoint B7-H4 and Lysine Demethylase 5B in Esophageal Squamous Cell Carcinoma Confers Protective Immunity against P. gingivalis Infection.
Changes of host DNA methylation in domestic chickens infected with Salmonella enterica.
RSV-Induced H3K4 Demethylase KDM5B Leads to Regulation of Dendritic Cell-Derived Innate Cytokines and Exacerbates Pathogenesis In Vivo.
The downregulation of GFI1 by the EZH2-NDY1/KDM2B-JARID2 axis and by human cytomegalovirus (HCMV) associated factors allows the activation of the HCMV major IE promoter and the transition to productive infection.
Insulin Resistance
The Lysine Demethylase KDM5B Regulates Islet Function and Glucose Homeostasis.
Intellectual Disability
A Mouse Model of X-linked Intellectual Disability Associated with Impaired Removal of Histone Methylation.
A novel c.2T > C mutation of the KDM5C/JARID1C gene in one large family with X-linked intellectual disability.
A novel de novo KDM5C variant in a female with global developmental delay and ataxia: a case report.
A novel mutation in JARID1C gene associated with mental retardation.
A novel nonsense mutation in KDM5C/JARID1C gene causing intellectual disability, short stature and speech delay.
A regulatory path associated with X-linked intellectual disability and epilepsy links KDM5C to the polyalanine expansions in ARX.
Altered Gene-Regulatory Function of KDM5C by a Novel Mutation Associated With Autism and Intellectual Disability.
Crystal structure of the PHF8 Jumonji domain, an Nepsilon-methyl lysine demethylase.
Different X-linked KDM5C Mutations in Affected Male Siblings: Is Maternal Reversion Error Involved?
DNA methylation fingerprint of monozygotic twins and their singleton sibling with intellectual disability carrying a novel KDM5C mutation.
Drosophila Histone Demethylase KDM5 Regulates Social Behavior through Immune Control and Gut Microbiota Maintenance.
Haploinsufficiency of two histone modifier genes on 6p22.3, ATXN1 and JARID2, is associated with intellectual disability.
Histone demethylase KDM5C is a SAHA-sensitive central hub at the crossroads of transcriptional axes involved in multiple neurodevelopmental disorders.
Identification of a RAI1-associated disease network through integration of exome sequencing, transcriptomics, and 3D genomics.
JARID2 haploinsufficiency is associated with a clinically distinct neurodevelopmental syndrome.
KDM5C mutational screening among males with intellectual disability suggestive of X-Linked inheritance and review of the literature.
Microdeletion of the escape genes KDM5C and IQSEC2 in a girl with severe intellectual disability and autistic features.
Molecular and cellular events linking variants in the histone demethylase KDM5C to the intellectual disability disorder Claes-Jensen syndrome.
Mutations in JARID1C are associated with X-linked mental retardation, short stature and hyperreflexia.
Mutations in the intellectual disability gene KDM5C reduce protein stability and demethylase activity.
Mutations of histone demethylase genes encoded by X and Y chromosomes, Kdm5c and Kdm5d, lead to noncompaction cardiomyopathy in mice.
Mutually suppressive roles of KMT2A and KDM5C in behaviour, neuronal structure, and histone H3K4 methylation.
Novel human pathological mutations. Gene symbol: JARID1C. Disease: mental retardation, X-linked.
Novel KDM5B splice variants identified in patients with developmental disorders: Functional consequences.
Patient Mutations of the Intellectual Disability Gene KDM5C Downregulate Netrin G2 and Suppress Neurite Growth in Neuro2a Cells.
Sex-specific expression of the X-linked histone demethylase gene Jarid1c in brain.
[Clinical features and gene variant of a pedigree affected with X-linked recessive mental retardation Claes-Jensen type].
[Clinical phenotype and genetic analysis of a Chinese patient featuring X-linked Claes-Jensen type syndromic mental retardation].
[Monogenic causes of X-linked mental retardation.]
[Progress on X-linked mental retardation related gene JARID1C.]
Ischemic Stroke
Decreased miR-146a expression in acute ischemic stroke directly targets the Fbxl10 mRNA and is involved in modulating apoptosis.
Kidney Neoplasms
Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.
Klinefelter Syndrome
Epigenetics and genomics in Turner syndrome.
Laminopathies
Identification of Genes and Pathways Regulated by Lamin A in Heart.
Learning Disabilities
Identification and characterization of two novel JARID1C mutations: suggestion of an emerging genotype-phenotype correlation.
Leukemia
Fbxl10 overexpression in murine hematopoietic stem cells induces leukemia involving metabolic activation and upregulation of Nsg2.
Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions.
Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene.
JARID1B deletion induced apoptosis in Jeko-1 and HL-60 cell lines.
JARID2 inhibits leukemia cell proliferation by regulating CCND1 expression.
Jarid2 is induced by TCR signalling and controls iNKT cell maturation.
Keeping methylation at bay.
NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX-gene expression pattern.
The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.
Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia.
[Research Advances in Lysine-specific Demethylase 6A and Its Application in Treating Leukemia].
[The effects of JARID1B siRNA on proliferation and apoptosis in HL-60 cell].
Leukemia, Lymphoid
JARID2 inhibits leukemia cell proliferation by regulating CCND1 expression.
Leukemia, Megakaryoblastic, Acute
NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX-gene expression pattern.
Leukemia, Monocytic, Acute
JARID2 inhibits leukemia cell proliferation by regulating CCND1 expression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions.
Leukemia, Myeloid, Acute
Identification and characterization of small molecule inhibitors of a plant homeodomain finger.
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.
Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view.
The histone demethylase Jarid1b is required for hematopoietic stem cell self-renewal.
Leukemia, Promyelocytic, Acute
[The effects of JARID1B siRNA on proliferation and apoptosis in HL-60 cell].
Liver Cirrhosis
Histone demethylase retinoblastoma binding protein 2 regulates the expression of ?-smooth muscle actin and vimentin in cirrhotic livers.
Liver Neoplasms
KDM5A silencing transcriptionally suppresses the FXYD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation.
Lung Neoplasms
Extended Recognition of the Histone H3 Tail by Histone Demethylase KDM5A.
Identification of Small Molecule Inhibitors of Jumonji AT-rich Interactive Domain 1B (JARID1B) Histone Demethylase by a Sensitive High Throughput Screen.
Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer.
JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression.
JARID2 is involved in transforming growth factor-beta-induced epithelial-mesenchymal transition of lung and colon cancer cell lines.
JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1.
KDM5C Expedites Lung Cancer Growth and Metastasis Through Epigenetic Regulation of MicroRNA-133a.
Long non-coding RNA KDM5B anti-sense RNA 1 enhances tumor progression in non-small cell lung cancer.
MEG3 Long Noncoding RNA Contributes to the Epigenetic Regulation of Epithelial-Mesenchymal Transition in Lung Cancer Cell Lines.
Metformin-induced chemosensitization to cisplatin depends on P53 status and is inhibited by Jarid1b overexpression in non-small cell lung cancer cells.
Overcoming of Radioresistance in Non-small Cell Lung Cancer by microRNA-320a Through HIF1?-Suppression Mediated Methylation of PTEN.
Predictive Value of KDM5C Alterations for Immune Checkpoint Inhibitors Treatment Outcomes in Patients With Cancer.
Retinoblastoma binding protein 2 (RBP2) promotes HIF-1?-VEGF-induced angiogenesis of non-small cell lung cancer via the Akt pathway.
Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis.
Y disruption, autosomal hypomethylation and poor male lung cancer survival.
Lymphatic Metastasis
Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor.
JARID1B expression in human melanoma and benign melanocytic skin lesions.
Prognostic value of elevated KDM5B expression in patients with laryngeal squamous cell carcinoma.
Lymphoma
JARID1B deletion induced apoptosis in Jeko-1 and HL-60 cell lines.
Members of a family of JmjC domain-containing oncoproteins immortalize embryonic fibroblasts via a JmjC domain-dependent process.
Lymphoma, B-Cell
FBXL10 contributes to the development of diffuse large B-cell lymphoma by epigenetically enhancing ERK1/2 signaling pathway.
Lymphoma, Large B-Cell, Diffuse
FBXL10 contributes to the development of diffuse large B-cell lymphoma by epigenetically enhancing ERK1/2 signaling pathway.
Lymphoma, Mantle-Cell
JARID1B deletion induced apoptosis in Jeko-1 and HL-60 cell lines.
Medulloblastoma
OTX2 sustains a bivalent-like state of OTX2-bound promoters in medulloblastoma by maintaining their H3K27me3 levels.
Melanoma
A role for the JARID1B stem cell marker for continuous melanoma growth.
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.
Altered Splicing of JARID1B in Development of Human Cutaneous Melanoma?
Depletion of JARID1B induces cellular senescence in human colorectal cancer.
Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade.
Epigenetic Regulation by Lysine Demethylase 5 (KDM5) Enzymes in Cancer.
Histone demethylase JARID1B/KDM5B is a corepressor of TIEG1/KLF10.
Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells.
JARID1-targeted histone H3 demethylase inhibitors exhibit anti-proliferative activity and overcome cisplatin resistance in canine oral melanoma cell lines.
JARID1B expression in human melanoma and benign melanocytic skin lesions.
JARID1B protein expression and prognostic implications in uveal melanoma.
JARID2 and the PRC2 complex regulate skeletal muscle differentiation through regulation of canonical Wnt signaling.
Jumonji/Arid1b (Jarid1b) protein modulates human esophageal cancer cell growth.
KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations.
MicroRNA-363-3p/p21(Cip1/Waf1) axis is regulated by HIF-2? in mediating stemness of melanoma cells.
Phenformin enhances the efficacy of ERK inhibition in NF1-mutant melanoma.
Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.
Prognostic significance of RBP2-H1 variant of JARID1B in melanoma.
Study of the Female Sex Survival Advantage in Melanoma-A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts.
Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma Cells.
Memory Disorders
A Mouse Model of X-linked Intellectual Disability Associated with Impaired Removal of Histone Methylation.
Short-term memory deficits in carrier females with KDM5C mutations.
Mental Retardation, X-Linked
A distinctive gene expression fingerprint in mentally retarded male patients reflects disease-causing defects in the histone demethylase KDM5C.
Cofactors-loaded quaternary structure of lysine-specific demethylase 5C (KDM5C) protein: Computational model.
Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression.
Identification of a RAI1-associated disease network through integration of exome sequencing, transcriptomics, and 3D genomics.
Mutations in JARID1C are associated with X-linked mental retardation, short stature and hyperreflexia.
Mutations in the JARID1C gene, which is involved in transcriptional regulation and chromatin remodeling, cause X-linked mental retardation.
Mutations in the KDM5C ARID Domain and Their Plausible Association with Syndromic Claes-Jensen-Type Disease.
Physiological effects of KDM5C on neural crest migration and eye formation during vertebrate development.
Screening of mutations in the PHF8 gene and identification of a novel mutation in a Finnish family with XLMR and cleft lip/cleft palate.
The histone H3K4 demethylase SMCX links REST target genes to X-linked mental retardation.
X-linked mental retardation and severe short stature with a novel mutation of the KDM5C gene.
[Progress on X-linked mental retardation related gene JARID1C.]
[Two cases of X-linked mental retardation, Claes-Jensen syndrome caused by variation of KDM5C gene].
Microcephaly
Identification of a RAI1-associated disease network through integration of exome sequencing, transcriptomics, and 3D genomics.
[Monogenic causes of X-linked mental retardation.]
Mouth Neoplasms
Correction: JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers.
JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers.
Movement Disorders
A novel de novo KDM5C variant in a female with global developmental delay and ataxia: a case report.
Multiple Endocrine Neoplasia
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.
Multiple Endocrine Neoplasia Type 1
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.
Multiple Myeloma
Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma.
Myelodysplastic Syndromes
Polycomb segment myeloid malignancies.
Myocardial Infarction
Protective effect of FBXL10 in myocardial ischemia reperfusion injury via inhibiting endoplasmic reticulum stress.
Myocardial Ischemia
Protective effect of FBXL10 in myocardial ischemia reperfusion injury via inhibiting endoplasmic reticulum stress.
Nasopharyngeal Carcinoma
FBXL10 contributes to the progression of nasopharyngeal carcinoma via involving in PI3K/mTOR pathway.
Histone demethylase KDM4A plays an oncogenic role in nasopharyngeal carcinoma by promoting cell migration and invasion.
Human umbilical cord mesenchymal stem cells-derived exosomal microRNA-181a retards nasopharyngeal carcinoma development by mediating KDM5C.
Neoplasm Metastasis
Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14.
Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.
Correction: JARID1B promotes metastasis and epithelial-mesenchymal transition via PTEN/AKT signaling in hepatocellular carcinoma cells.
ETV4 promotes the progression of gastric cancer through regulating KDM5D.
Evidence of Omics, Immune Infiltration, and Pharmacogenomic for SENP1 in the Pan-Cancer Cohort.
Expression profile of H3K4 demethylases with their clinical and pathological correlation in patients with clear cell renal cell carcinoma.
Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor.
Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression.
Histone demethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1.
Histone demethylase KDM5A promotes tumorigenesis of osteosarcoma tumor.
Histone demethylase lysine demethylase 5B in development and cancer.
Hypoxia promotes the metastasis of pancreatic cancer through regulating NOX4/KDM5A-mediated histone methylation modification changes in a HIF1A-independent manner.
Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells.
JARID1B expression in human melanoma and benign melanocytic skin lesions.
JARID1B promotes metastasis and epithelial-mesenchymal transition via PTEN/AKT signaling in hepatocellular carcinoma cells.
JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
JARID2 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition through PTEN/AKT signaling.
KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.
KDM5A promotes proliferation and EMT in ovarian cancer and closely correlates with PTX resistance.
KDM5B is overexpressed in gastric cancer and is required for gastric cancer cell proliferation and metastasis.
KDM5B promotes breast cancer cell proliferation and migration via AMPK-mediated lipid metabolism reprogramming.
KDM5C Expedites Lung Cancer Growth and Metastasis Through Epigenetic Regulation of MicroRNA-133a.
KDM5C Represses FASN-Mediated Lipid Metabolism to Exert Tumor Suppressor Activity in Intrahepatic Cholangiocarcinoma.
KDM5D inhibit epithelial-mesenchymal transition of gastric cancer through demethylation in the promoter of Cul4A in male.
Knockdown of JARID2 inhibits the viability and migration of placenta trophoblast cells in preeclampsia.
Long intergenic non-protein-coding RNA 01446 facilitates the proliferation and metastasis of gastric cancer cells through interacting with the histone lysine-specific demethylase LSD1.
LSD1 Promotes Bladder Cancer Progression by Upregulating LEF1 and Enhancing EMT.
Lysine-specific demethylase 5C promotes hepatocellular carcinoma cell invasion through inhibition BMP7 expression.
Prognostic value of elevated KDM5B expression in patients with laryngeal squamous cell carcinoma.
Retinoblastoma-binding protein 2 (RBP2) is frequently expressed in neuroendocrine tumors and promotes the neoplastic phenotype.
Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines.
The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis.
Neoplasms
A KDM5 Inhibitor Increases Global H3K4 Trimethylation Occupancy and Enhances the Biological Efficacy of 5-Aza-2'-Deoxycytidine.
A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer.
A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolism.
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.
Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression.
Altered Splicing of JARID1B in Development of Human Cutaneous Melanoma?
Analysis of key genes reveal lysine demethylase 5B promotes prostate cancer progression.
Association between visceral adiposity and DDX11 as a predictor of aggressiveness of small clear-cell renal-cell carcinoma: a prospective clinical trial.
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.
Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14.
Blockade of Immune-Checkpoint B7-H4 and Lysine Demethylase 5B in Esophageal Squamous Cell Carcinoma Confers Protective Immunity against P. gingivalis Infection.
Characterisation and developmental expression of mouse Plu-1, a homologue of a human nuclear protein (PLU-1) which is specifically up-regulated in breast cancer.
Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations.
cis-Cyclopropylamines as mechanism-based inhibitors of Monoamine Oxidases.
Comprehensive Genomic Profiling of Renal Cell Carcinoma at Initial Diagnosis and Putative Local Recurrence.
Connexin 26 is Down-Regulated by KDM5B in the Progression of Bladder Cancer.
Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma.
Deficiency of the X-inactivation escaping gene KDM5C in clear cell renal cell carcinoma promotes tumorigenicity by reprogramming glycogen metabolism and inhibiting ferroptosis.
Depletion of Histone Demethylase Jarid1A Resulting in Histone Hyperacetylation and Radiation Sensitivity Does Not Affect DNA Double-Strand Break Repair.
Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27.
Depletion of JARID1B induces cellular senescence in human colorectal cancer.
Design, Synthesis, and Biological Evaluation of Lysine Demethylase 5?C Degraders.
Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B).
E6 Protein Expressed by High-Risk HPV Activates Super-Enhancers of the
Effects of Histone Deacetylase Inhibitors on Modulating H3K4 Methylation Marks - A Novel Cross-Talk Mechanism between Histone-Modifying Enzymes.
Endometrial cancer with an EML4-ALK rearrangement.
Endothelial Jarid2/Jumonji is required for normal cardiac development and proper Notch1 expression.
Enhancement of Proliferation and Invasion of Gastric Cancer Cell by KDM5C Via Decrease in p53 Expression.
Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade.
Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways.
Epigenetic modifiers: activities in renal cell carcinoma.
Epigenetic regulation in RCC: opportunities for therapeutic intervention?
Evaluation of histone-modifying enzymes in stem cell populations.
Evidence for context-dependent functions of KDM5B in prostate development and prostate cancer.
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.
Expanding the Role of the Histone Lysine-Specific Demethylase LSD1 in Cancer.
Expression of Lysine-specific demethylase 1 in human epithelial ovarian cancer.
Expression profile of H3K4 demethylases with their clinical and pathological correlation in patients with clear cell renal cell carcinoma.
Extended Recognition of the Histone H3 Tail by Histone Demethylase KDM5A.
F-box protein 10, an NF-?B-dependent anti-apoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathway.
FBXL10 contributes to the development of diffuse large B-cell lymphoma by epigenetically enhancing ERK1/2 signaling pathway.
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.
Gender Specific Mutation Incidence and Survival Associations in Clear Cell Renal Cell Carcinoma (CCRCC).
Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA.
Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer.
Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection.
Genomic Landscape of Chinese Clear Cell Renal Cell Carcinoma Patients With Venous Tumor Thrombus Identifies Chromosome 9 and 14 Deletions and Related Immunosuppressive Microenvironment.
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Getting to the heart of the matter in cancer: Novel approaches to targeting cancer stem cells.
H3K4 demethylation by Jarid1a and Jarid1b contributes to retinoblastoma-mediated gene silencing during cellular senescence.
Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation, in part, via transcriptional repression of histone H3 lysine 4 demethylases.
Histone Demethylase JARID1B is Overexpressed in Osteosarcoma and Upregulates Cyclin D1 Expression Via Demethylation of H3K27me3.
Histone demethylase JARID1B promotes cell proliferation but is downregulated by N-Myc oncoprotein.
Histone demethylase JARID1B/KDM5B is a corepressor of TIEG1/KLF10.
Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor.
Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.
Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression.
Histone demethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1.
Histone demethylase KDM5A promotes tumorigenesis of osteosarcoma tumor.
Histone Demethylase KDM5B as a Therapeutic Target for Cancer Therapy.
Histone demethylase lysine demethylase 5B in development and cancer.
Histone demethylase PHF8 promotes cell growth and metastasis of non-small-cell lung cancer through activating Wnt/?-catenin signaling pathway.
Histone H3 binding to the PHD1 domain of histone demethylase KDM5A enables active site remodeling.
Human papillomavirus type 16 E7 oncoprotein-induced upregulation of lysine-specific demethylase 5A promotes cervical cancer progression by regulating the microRNA-424-5p/suppressor of zeste 12 pathway.
Human PLU-1 Has transcriptional repression properties and interacts with the developmental transcription factors BF-1 and PAX9.
Human umbilical cord mesenchymal stem cells-derived exosomal microRNA-181a retards nasopharyngeal carcinoma development by mediating KDM5C.
Hypoxia Induces Trimethylated H3 Lysine 4 by Inhibition of JARID1A Demethylase.
Identification of Genes and Pathways Regulated by Lamin A in Heart.
Identification of Small Molecule Inhibitors of Jumonji AT-rich Interactive Domain 1B (JARID1B) Histone Demethylase by a Sensitive High Throughput Screen.
Immunohistochemical detection and clinicopathological significance of JARID1B/KDM5B and P16 expression in invasive ductal carcinoma of the breast.
Impairment of Preimplantation Porcine Embryo Development by Histone Demethylase KDM5B Knockdown Through Disturbance of Bivalent H3K4me3-H3K27me3 Modifications.
In vitro evidence of NLRP3 inflammasome regulation by histone demethylase LSD2 in renal cancer: a pilot study.
Increased Expression of Lysine-Specific Demethylase 5B (KDM5B) Promotes Tumor Cell Growth in Hep3B Cells and is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma.
Increased mitochondrial function downstream from KDM5A histone demethylase rescues differentiation in pRB-deficient cells.
Inhibition of Jumonji Histone Demethylases Selectively Suppresses HER2+ Breast Leptomeningeal Carcinomatosis Growth via Inhibition of GMCSF Expression.
Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells.
Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy.
JARID1 Histone Demethylases: Emerging Targets in Cancer.
JARID1-targeted histone H3 demethylase inhibitors exhibit anti-proliferative activity and overcome cisplatin resistance in canine oral melanoma cell lines.
JARID1B expression in human melanoma and benign melanocytic skin lesions.
JARID1B Expression Plays a Critical Role in Chemoresistance and Stem Cell-Like Phenotype of Neuroblastoma Cells.
JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression.
JARID1B promotes colorectal cancer proliferation and Wnt/?-catenin signaling via decreasing CDX2 level.
JARID1B promotes metastasis and epithelial-mesenchymal transition via PTEN/AKT signaling in hepatocellular carcinoma cells.
JARID1B protein expression and prognostic implications in uveal melanoma.
JARID2 and the PRC2 complex regulate skeletal muscle differentiation through regulation of canonical Wnt signaling.
JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells.
JARID2 inhibits leukemia cell proliferation by regulating CCND1 expression.
JARID2 Is a Tumor Suppressor in Myeloid Neoplasms.
Jarid2 is essential for the maintenance of tumor initiating cells in bladder cancer.
JARID2 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition through PTEN/AKT signaling.
JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1.
Jumonji AT-rich interactive domain 1B overexpression is associated with the development and progression of glioma.
Jumonji AT-rich interactive domain 1B promotes the growth of pancreatic tumors via the phosphatase and tensin homolog/protein kinase B signaling pathway.
Jumonji Inhibitors Overcome Radioresistance in Cancer through Changes in H3K4 Methylation at Double-Strand Breaks.
Jumonji/ARID1 B (JARID1B) protein promotes breast tumor cell cycle progression through epigenetic repression of microRNA let-7e.
Jumonji/Arid1b (Jarid1b) protein modulates human esophageal cancer cell growth.
KDM5 histone demethylases repress immune response via suppression of STING.
KDM5A and KDM5B histone-demethylases contribute to HU-induced replication stress response and tolerance.
KDM5A Regulates a Translational Program that Controls p53 Protein Expression.
KDM5A silencing transcriptionally suppresses the FXYD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation.
KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance.
KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family.
KDM5B is a master regulator of the H3K4-methylome in stem cells, development and cancer.
KDM5B is essential for the hyper-activation of PI3K/AKT signaling in prostate tumorigenesis.
KDM5B is overexpressed in gastric cancer and is required for gastric cancer cell proliferation and metastasis.
KDM5B promotes breast cancer cell proliferation and migration via AMPK-mediated lipid metabolism reprogramming.
KDM5B promotes self-renewal of hepatocellular carcinoma cells through the microRNA-448-mediated YTHDF3/ITGA6 axis.
KDM5B-mediated microRNA-448 up-regulation restrains papillary thyroid cancer cell progression and slows down tumor growth via TGIF1 repression.
KDM5C Expedites Lung Cancer Growth and Metastasis Through Epigenetic Regulation of MicroRNA-133a.
KDM5c inhibits multidrug resistance of colon cancer cell line by down-regulating ABCC1.
KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy.
KDM5C Represses FASN-Mediated Lipid Metabolism to Exert Tumor Suppressor Activity in Intrahepatic Cholangiocarcinoma.
KDM5D inhibit epithelial-mesenchymal transition of gastric cancer through demethylation in the promoter of Cul4A in male.
LncRNA TNK2-AS1/miR-125a-5p axis promotes tumor growth and modulated PI3K/AKT pathway.
Long non-coding RNA KDM5B anti-sense RNA 1 enhances tumor progression in non-small cell lung cancer.
Loss of PBRM1 expression is associated with renal cell carcinoma progression.
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.
LSD1 Promotes Bladder Cancer Progression by Upregulating LEF1 and Enhancing EMT.
LSD1 regulates Notch and PI3K/Akt/mTOR pathways through binding the promoter regions of Notch target genes in esophageal squamous cell carcinoma.
Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target.
Lysine demethylase 5B suppresses CC chemokine ligand 14 to promote progression of colorectal cancer through the Wnt/?-catenin pathway.
Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma.
Lysine-specific demethylase 2A expression is associated with cell growth and cyclin D1 expression in colorectal adenocarcinoma.
Lysine-specific demethylase 5C promotes hepatocellular carcinoma cell invasion through inhibition BMP7 expression.
Lysine-specific demethylase LSD1 regulates autophagy in neuroblastoma through SESN2-dependent pathway.
MEG3 Long Noncoding RNA Contributes to the Epigenetic Regulation of Epithelial-Mesenchymal Transition in Lung Cancer Cell Lines.
Melatonin exerts anti-oral cancer effect via suppressing LSD1 in patient-derived tumor xenograft models.
Metastatic renal cell carcinoma without evidence of a renal primary.
Metformin-induced chemosensitization to cisplatin depends on P53 status and is inhibited by Jarid1b overexpression in non-small cell lung cancer cells.
microRNA-139-3p Inhibits Malignant Behaviors of Laryngeal Cancer Cells via the KDM5B/SOX2 Axis and the Wnt/?-Catenin Pathway.
microRNA-181a promotes the oncogene S100A2 and enhances papillary thyroid carcinoma growth by mediating the expression of histone demethylase KDM5C.
microRNA-206 Suppresses Cholangiocarcinoma Cell Growth and Invasion by Targeting Jumonji AT-Rich Interactive Domain 2.
microRNA-486-5p functions as a tumor suppressor in gastric carcinoma via directly targeting KDM5B.
miR-194 inhibits gastric cancer cell proliferation and tumorigenesis by targeting KDM5B.
MiR-29a suppresses prostate cell proliferation and induces apoptosis via KDM5B protein regulation.
MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators.
miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis.
Molecular analysis of PRC2 recruitment to DNA in chromatin and its inhibition by RNA.
mRNA expression profiling of histone modifying enzymes in pediatric acute monoblastic leukemia.
Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma.
New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein.
Overexpressed KDM5B is associated with the progression of glioma and promotes glioma cell growth via downregulating p21.
Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer.
Overexpression of JARID1B promotes differentiation via SHIP1/AKT signaling in human hypopharyngeal squamous cell carcinoma.
Overexpression of Jumonji AT-rich interactive domain 1B and PHD finger protein 2 is involved in the progression of esophageal squamous cell carcinoma.
Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway.
p21WAF-1 reorganizes the nucleus in tumor suppression.
Personalized Survival Prediction of Patients With Acute Myeloblastic Leukemia Using Gene Expression Profiling.
Phosphorylation of the histone demethylase KDM5B and regulation of the phenotype of triple negative breast cancer.
Physiological effects of KDM5C on neural crest migration and eye formation during vertebrate development.
PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer.
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation.
PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/testis antigen?
PLU-1, a transcriptional repressor and putative testis-cancer antigen, has a specific expression and localisation pattern during meiosis.
PLU-1/JARID1B/KDM5B is required for embryonic survival and contributes to cell proliferation in the mammary gland and in ER+ breast cancer cells.
Polycomb segment myeloid malignancies.
Positive Expression of LSD1 and Negative Expression of E-cadherin Correlate with Metastasis and Poor Prognosis of Colon Cancer.
Prediction of High-Grade Clear Cell Renal Cell Carcinoma Based on Plasma mRNA Profiles in Patients with Localized Pathologic T1N0M0 Stage Disease.
Predictive Value of KDM5C Alterations for Immune Checkpoint Inhibitors Treatment Outcomes in Patients With Cancer.
Prognostic significance of RBP2-H1 variant of JARID1B in melanoma.
Prognostic value of elevated KDM5B expression in patients with laryngeal squamous cell carcinoma.
Proteomics and metabolomics identify molecular mechanisms of aging potentially predisposing for chronic lymphocytic leukemia.
Recognition of Histone H3 Methylation States by the PHD1 Domain of Histone Demethylase KDM5A.
Reduced expression of Jumonji, AT-rich interactive domain 2 (JARID2) in glioma inhibits tumor growth in vitro and in vivo.
Relevance of c-erbB2, PLU-1 and survivin mRNA expression to diagnostic assessment of breast cancer.
Reticuloendotheliosis virus strain T induces miR-155 which targets JARID2 and promotes cell survival.
Retinoblastoma binding protein 2 (RBP2) promotes HIF-1?-VEGF-induced angiogenesis of non-small cell lung cancer via the Akt pathway.
Retinoblastoma-binding protein 2 (RBP2) is frequently expressed in neuroendocrine tumors and promotes the neoplastic phenotype.
Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
Silencing JARID1B suppresses oncogenicity, stemness and increases radiation sensitivity in human oral carcinoma.
SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination.
Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines.
Studies on the Interaction of the Histone Demethylase KDM5B with Tricarboxylic Acid Cycle Intermediates.
Study of the Female Sex Survival Advantage in Melanoma-A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts.
Targeting histone demethylase KDM5B for cancer treatment.
Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view.
Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer.
Targeting KDM1B-dependent miR-215-AR-AGR2-axis promotes sensitivity to enzalutamide-resistant prostate cancer.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
The emerging role of KDM5A in human cancer.
The histone demethylase KDM5b/JARID1b plays a role in cell fate decisions by blocking terminal differentiation.
The Human Melanoma Side Population Displays Molecular and Functional Characteristics of Enriched Chemoresistance and Tumorigenesis.
The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.
The KDM5 family of histone demethylases as targets in oncology drug discovery.
The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis.
The PcG protein hPc2 interacts with the N-terminus of histone demethylase JARID1B and acts as a transcriptional co-repressor.
The PHD1 finger of KDM5B recognizes unmodified H3K4 during the demethylation of histone H3K4me2/3 by KDM5B.
The retinoblastoma binding protein RBP2 is an H3K4 demethylase.
The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
Transcriptomic Features of T Cell-Barren Tumors Are Conserved Across Diverse Tumor Types.
Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile.
Tumor mutation burden and JARID2 gene alteration are associated with short disease-free survival in locally advanced triple-negative breast cancer.
Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency.
Y disruption, autosomal hypomethylation and poor male lung cancer survival.
[Application of human adipose-derived stromal cells in bone tissue engineering].
Neoplasms, Squamous Cell
Overexpression of JARID1B promotes differentiation via SHIP1/AKT signaling in human hypopharyngeal squamous cell carcinoma.
Neural Tube Defects
Fbxl10/Kdm2b deficiency accelerates neural progenitor cell death and leads to exencephaly.
The histone demethylase Jarid1b ensures faithful mouse development by protecting developmental genes from aberrant H3K4me3.
Neuroblastoma
Histone demethylase JARID1B promotes cell proliferation but is downregulated by N-Myc oncoprotein.
JARID1B Expression Plays a Critical Role in Chemoresistance and Stem Cell-Like Phenotype of Neuroblastoma Cells.
Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma.
Lysine-specific demethylase LSD1 regulates autophagy in neuroblastoma through SESN2-dependent pathway.
Patient Mutations of the Intellectual Disability Gene KDM5C Downregulate Netrin G2 and Suppress Neurite Growth in Neuro2a Cells.
Nevus
JARID1B expression in human melanoma and benign melanocytic skin lesions.
Osteopetrosis
Diversity of copy number variation in the worldwide goat population.
Osteoporosis
KDM5A controls bone morphogenic protein 2-induced osteogenic differentiation of bone mesenchymal stem cells during osteoporosis.
Osteosarcoma
Histone Demethylase JARID1B is Overexpressed in Osteosarcoma and Upregulates Cyclin D1 Expression Via Demethylation of H3K27me3.
Histone demethylase KDM5A promotes tumorigenesis of osteosarcoma tumor.
Ovarian Neoplasms
KDM5A promotes proliferation and EMT in ovarian cancer and closely correlates with PTX resistance.
Knockdown of JARID2 inhibits the proliferation and invasion of ovarian cancer through the PI3K/Akt signaling pathway.
Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
MiR-135b-5p affected malignant behaviors of ovarian cancer cells by targeting KDM5B.
miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.
Promotion of Cell Death in Cisplatin-Resistant Ovarian Cancer Cells through KDM1B-DCLRE1B Modulation.
Targeting of KDM5A by miR-421 in Human Ovarian Cancer Suppresses the Progression of Ovarian Cancer Cells.
Pancreatic Neoplasms
Knockdown of KDM1B inhibits cell proliferation and induces apoptosis of pancreatic cancer cells.
Papilloma
KDM5 histone demethylases repress immune response via suppression of STING.
Persistent Infection
Blockade of Immune-Checkpoint B7-H4 and Lysine Demethylase 5B in Esophageal Squamous Cell Carcinoma Confers Protective Immunity against P. gingivalis Infection.
Pinealoma
Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome.
Pre-Eclampsia
Knockdown of JARID2 inhibits the viability and migration of placenta trophoblast cells in preeclampsia.
Redox-Sensitive Transcription Factor NRF2 Enhances Trophoblast Differentiation via Induction of miR-1246 and Aromatase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Down-regulation of JARID1B expression inhibits cell proliferation, induces apoptosis and blocks cell cycle in human acute lymphoblastic leukemia cells.
MiR-137 inhibits cell proliferation in acute lymphoblastic leukemia by targeting JARID1B.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Dynamic of broad H3K4me3 domains uncover an epigenetic switch between cell identity and cancer-related genes.
Prostatic Neoplasms
Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression.
AKT Inhibition Modulates H3K4 Demethylase Levels in PTEN-Null Prostate Cancer.
Analysis of key genes reveal lysine demethylase 5B promotes prostate cancer progression.
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.
Design, Synthesis, and Biological Evaluation of Lysine Demethylase 5?C Degraders.
Evidence for context-dependent functions of KDM5B in prostate development and prostate cancer.
Extended Recognition of the Histone H3 Tail by Histone Demethylase KDM5A.
Histone Demethylase KDM5B as a Therapeutic Target for Cancer Therapy.
Identification of Small Molecule Inhibitors of Jumonji AT-rich Interactive Domain 1B (JARID1B) Histone Demethylase by a Sensitive High Throughput Screen.
Investigation of Histone Lysine-Specific Demethylase 5D KDM5D) Isoform Expression in Prostate Cancer Cell Lines: a System Approach.
JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer.
JARID1D Is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis.
KDM5B is essential for the hyper-activation of PI3K/AKT signaling in prostate tumorigenesis.
KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy.
KDM5C is transcriptionally regulated by BRD4 and promotes castration-resistance prostate cancer cell proliferation by repressing PTEN.
Re: Resistance to Docetaxel in Prostate Cancer is Associated with Androgen Receptor Activation and Loss of KDM5D Expression.
Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination.
Targeting KDM1B-dependent miR-215-AR-AGR2-axis promotes sensitivity to enzalutamide-resistant prostate cancer.
Two Splice Variants of Y Chromosome-Located Lysine-Specific Demethylase 5D Have Distinct Function in Prostate Cancer Cell Line (DU-145).
Reflex, Abnormal
Mutations in JARID1C are associated with X-linked mental retardation, short stature and hyperreflexia.
Renal Insufficiency
The therapeutic effect of dexmedetomidine on protection from renal failure via inhibiting KDM5A in lipopolysaccharide-induced sepsis of mice.
Reperfusion Injury
Protective effect of FBXL10 in myocardial ischemia reperfusion injury via inhibiting endoplasmic reticulum stress.
Respiratory Insufficiency
The histone demethylase Jarid1b ensures faithful mouse development by protecting developmental genes from aberrant H3K4me3.
Retinoblastoma
A protein with similarity to the human retinoblastoma binding protein 2 acts specifically as a repressor for genes regulated by the b mating type locus in Ustilago maydis.
A screen for new trithorax group genes identified little imaginal discs, the Drosophila melanogaster homologue of human retinoblastoma binding protein 2.
An ARID family protein binds to the African swine fever virus encoded ubiquitin conjugating enzyme, UBCv1.
Chromatin remodeling: demethylating H3K4me3 of type I IFNs gene by Rbp2 through interacting with Piasy for transcriptional attenuation.
Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis.
Crosstalk between VEGF and novel angiogenic protein regulates tumor angiogenesis and contributes to aggressiveness of breast carcinoma.
Differential specificity for binding of retinoblastoma binding protein 2 to RB, p107, and TATA-binding protein.
H3K4 demethylation by Jarid1a and Jarid1b contributes to retinoblastoma-mediated gene silencing during cellular senescence.
Histone demethylase KDM5A is regulated by its reader domain through a positive-feedback mechanism.
Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212.
Histone demethylase retinoblastoma binding protein 2 regulates the expression of ?-smooth muscle actin and vimentin in cirrhotic livers.
Identification of Genes and Pathways Regulated by Lamin A in Heart.
Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene.
Inhibition of osteogenic differentiation of human adipose-derived stromal cells by retinoblastoma binding protein 2 repression of RUNX2-activated transcription.
Isolation and chromosomal localization of a new human retinoblastoma binding protein 2 homologue 1a (RBBP2H1A).
Isolation and regional assignment of human chromosome 12p cDNAs.
Isolation of the Rb-related p130 through its interaction with CDK2 and cyclins.
JARID2 and the PRC2 complex regulate the cell cycle in skeletal muscle.
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.
MicroRNA-212 inhibits proliferation of gastric cancer by directly repressing retinoblastoma binding protein 2.
MiR-34a Promotes Osteogenic Differentiation of Human Adipose-Derived Stem Cells via the RBP2/NOTCH1/CYCLIN D1 Coregulatory Network.
Retinoblastoma binding protein 2 (RBP2) promotes HIF-1?-VEGF-induced angiogenesis of non-small cell lung cancer via the Akt pathway.
siRNA targeting RBP2 inhibits expression, proliferation, tumorigenicity and invasion in thyroid carcinoma cells.
The nanoscale geometry of TiO2 nanotubes influences the osteogenic differentiation of human adipose-derived stem cells by modulating H3K4 trimethylation.
The retinoblastoma binding protein RBP2 is an H3K4 demethylase.
[Application of human adipose-derived stromal cells in bone tissue engineering].
[Inhibition of retinoblastoma binding protein 2 promotes osteogenic differentiation of human adipose-derived stromal cells].
Rhabdomyosarcoma
JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
Sarcoma
In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC).
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Sarcoma, Ewing
KDM5A and PHF2 positively control expression of pro-metastatic genes repressed by EWS/Fli1, and promote growth and metastatic properties in Ewing sarcoma.
Seizures
Novel microduplications at Xp11.22 including HUWE1: clinical and molecular insights into these genomic rearrangements associated with intellectual disability.
Sepsis
The therapeutic effect of dexmedetomidine on protection from renal failure via inhibiting KDM5A in lipopolysaccharide-induced sepsis of mice.
Skin Neoplasms
Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor.
Spondylitis, Ankylosing
JARID1A, JMY, and PTGER4 Polymorphisms Are Related to Ankylosing Spondylitis in Chinese Han Patients: A Case-Control Study.
The histone demethylase JARID1A is associated with susceptibility to ankylosing spondylitis.
Squamous Cell Carcinoma of Head and Neck
Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection.
Overexpression of JARID1B promotes differentiation via SHIP1/AKT signaling in human hypopharyngeal squamous cell carcinoma.
Prognostic value of elevated KDM5B expression in patients with laryngeal squamous cell carcinoma.
Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer.
[Sonic hedgehog signaling enhanced the expression of histone demethylase, lysine-specific demethylase 8 in the head and neck squamous cell carcinoma cell line SCC-6].
Stomach Neoplasms
Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B).
ELK4 promotes the development of gastric cancer by inducing M2 polarization of macrophages through regulation of the KDM5A-PJA2-KSR1 axis.
Enhancement of Proliferation and Invasion of Gastric Cancer Cell by KDM5C Via Decrease in p53 Expression.
ETV4 promotes the progression of gastric cancer through regulating KDM5D.
Extended Recognition of the Histone H3 Tail by Histone Demethylase KDM5A.
Histone demethylase KDM5A is regulated by its reader domain through a positive-feedback mechanism.
Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212.
Increased Mars2 expression upon microRNA-4661-5p-mediated KDM5D downregulation is correlated with malignant degree of gastric cancer cells.
KDM5B is overexpressed in gastric cancer and is required for gastric cancer cell proliferation and metastasis.
KDM5D inhibit epithelial-mesenchymal transition of gastric cancer through demethylation in the promoter of Cul4A in male.
Long intergenic non-protein-coding RNA 01446 facilitates the proliferation and metastasis of gastric cancer cells through interacting with the histone lysine-specific demethylase LSD1.
MicroRNA-212 inhibits proliferation of gastric cancer by directly repressing retinoblastoma binding protein 2.
miR-194 inhibits gastric cancer cell proliferation and tumorigenesis by targeting KDM5B.
TRIM15 Exerts Anti-Tumor Effects Through Suppressing Cancer Cell Invasion in Gastric Adenocarcinoma.
Stroke
X chromosome escapee genes are involved in ischemic sexual dimorphism through epigenetic modification of inflammatory signals.
Thyroid Cancer, Papillary
microRNA-181a promotes the oncogene S100A2 and enhances papillary thyroid carcinoma growth by mediating the expression of histone demethylase KDM5C.
siRNA targeting RBP2 inhibits expression, proliferation, tumorigenicity and invasion in thyroid carcinoma cells.
Tics
Jarid2 is essential for the maintenance of tumor initiating cells in bladder cancer.
Triple Negative Breast Neoplasms
Phosphorylation of the histone demethylase KDM5B and regulation of the phenotype of triple negative breast cancer.
Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy.
The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers.
Tumor mutation burden and JARID2 gene alteration are associated with short disease-free survival in locally advanced triple-negative breast cancer.
Urinary Bladder Neoplasms
Connexin 26 is Down-Regulated by KDM5B in the Progression of Bladder Cancer.
Jarid2 enhances the progression of bladder cancer through regulating PTEN/AKT signaling.
Jarid2 is essential for the maintenance of tumor initiating cells in bladder cancer.
Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway.
Uterine Cervical Neoplasms
E6 Protein Expressed by High-Risk HPV Activates Super-Enhancers of the
Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways.
HPV16 E7-induced upregulation of KDM2A promotes cervical cancer progression by regulating miR-132-radixin pathway.
Human papillomavirus type 16 E7 oncoprotein-induced upregulation of lysine-specific demethylase 5A promotes cervical cancer progression by regulating the microRNA-424-5p/suppressor of zeste 12 pathway.
miR424-5p functions as an anti-oncogene in cervical cancer cell growth by targeting KDM5B via the Notch signaling pathway.
Virus Diseases
Genome-Wide Association Study Identifies Loci Associated with Resistance to Viral Nervous Necrosis Disease in Asian Seabass.
[histone h3]-trimethyl-l-lysine4 demethylase deficiency
A distinctive gene expression fingerprint in mentally retarded male patients reflects disease-causing defects in the histone demethylase KDM5C.
Deficiency of the X-inactivation escaping gene KDM5C in clear cell renal cell carcinoma promotes tumorigenicity by reprogramming glycogen metabolism and inhibiting ferroptosis.
Effect of histone demethylase KDM5A on the odontogenic differentiation of human dental pulp cells.
Fbxl10/Kdm2b deficiency accelerates neural progenitor cell death and leads to exencephaly.
H3K4me3 Demethylase Kdm5a Is Required for NK Cell Activation by Associating with p50 to Suppress SOCS1.
Histone demethylase KDM5A regulates the ZMYND8-NuRD chromatin remodeler to promote DNA repair.
Histone demethylase KDM5B is a key regulator of genome stability.
Inactive yet indispensable: the tale of Jarid2.
Jarid2 regulates mouse epidermal stem cell activation and differentiation.
KDM5B is essential for the hyper-activation of PI3K/AKT signaling in prostate tumorigenesis.
Y disruption, autosomal hypomethylation and poor male lung cancer survival.